# Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy

Study · id `cardio:ct-nct05180773` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05180773](<https://clinicaltrials.gov/study/NCT05180773>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05180773

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 250 participants.

## Technical summary

Registry record NCT05180773. Randomized; quadruple masking; primary purpose treatment. Start 2022-07-27 (actual); primary completion 2028-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 250 participants (planned count; ClinicalTrials.gov record NCT05180773, source copy `cardio:ctgov-nct05180773-2026-08-10`, retrieved 2026-10-31)
- Started: 2022-07-27 (actual) (ClinicalTrials.gov record NCT05180773, source copy `cardio:ctgov-nct05180773-2026-08-10`, retrieved 2026-10-31)
- Primary completion: 2028-06-30 (anticipated) (ClinicalTrials.gov record NCT05180773, source copy `cardio:ctgov-nct05180773-2026-08-10`, retrieved 2026-10-31)
- Completion: 2028-12-31 (anticipated) (ClinicalTrials.gov record NCT05180773, source copy `cardio:ctgov-nct05180773-2026-08-10`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT05180773, source copy `cardio:ctgov-nct05180773-2026-08-10`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05180773-2026-08-10`, retrieved 2026-10-31)

## The registry's words

- Brief title: Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
- Acronym: REBIRTH
- Condition: Peripartum Cardiomyopathy, Postpartum
- Intervention (Drug): Bromocriptine
- Intervention (Drug): Placebo
- Intervention (Drug): Guideline Directed Medical Therapy for Heart Failure (GDMT)
- Intervention (Drug): Rivaroxaban
- Intervention (Drug): Second Placebo
- Lead sponsor: Dennis M. McNamara, MD, MS
- Lead sponsor class: OTHER
- Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Peripartum cardiomyopathy (`core:peripartum-cardiomyopathy`)
- Registry intervention name matches this record: Rivaroxaban (`cardio:rivaroxaban`)
- Registry lists this organization as a collaborator: National Heart, Lung, and Blood Institute (`cardio:nhlbi`)

## Provenance

Content hash: 3cddeacc9c0e8a2607cc9284a71ce387dc8ad0d748e223ddb5d9cb9662cb3197
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
